Ka Neng Cheong
Research Subjects
Ka Neng Cheong has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Rockland Luke Wiseman
The Scripps Research Institute
2 shared publications Adrian Guerrero
Department of Chemistry
1 shared publicationAlejandra Mendoza
Department of Immunology and Microbial Science
1 shared publication- Alejandra Mendoza
Scripps Research
1 shared publication - Andrew B. Ward
Department of Integrative Structural and Computational Biology, The Scripps Research Institute
1 shared publication Aparajita Madhavan
Department of Molecular and Cellular Biology
1 shared publication
Latest Publications
- Open Access
Maternal antiviral history synergizes with pregnancy and lactation to transfer intergenerational systemic immunity through IgG in milk
Maternal immune transfer is essential for early-life health, yet whether immune experiences before pregnancy shape maternal physiology to optimize immunity in subsequent offspring is unclear. Here, we show that respiratory viral infection before pregnancy confers robust protection against lethal neonatal influenza through antibodies transferred postpartum in milk. Despite the predominance of IgA in milk, antiviral IgG is indispensable for protection. Pregnancy amplifies pre-existing antiviral B cell responses, while prior infection durably reprograms the mammary gland to promote transfer of circulating antiviral IgG into milk. These antibodies retain their epitope specificity, are enriched for broadly protective influenza epitopes, remain functional after passage through the neonatal intestine, and enter offspring circulation through FcRn to provide protection beyond weaning. Natural transmission of virus from infected offspring to mothers establishes maternal immunity that protects future offspring, revealing a coordinated adaptive program that links maternal immune history, pregnancy, and lactation to optimize intergenerational immunity.
Open AccessMaternal antiviral history synergizes with pregnancy and lactation to transfer intergenerational systemic immunity through IgG in milk
Maternal immune transfer is essential for early-life health, yet whether immune experiences before pregnancy shape maternal physiology to optimize immunity in subsequent offspring is unclear. Here, we show that respiratory viral infection before pregnancy confers robust protection against lethal neonatal influenza through antibodies transferred postpartum in milk. Despite the predominance of IgA in milk, antiviral IgG is indispensable for protection. Pregnancy amplifies pre-existing antiviral B cell responses, while prior infection durably reprograms the mammary gland to promote transfer of circulating antiviral IgG into milk. These antibodies retain their epitope specificity, are enriched for broadly protective influenza epitopes, remain functional after passage through the neonatal intestine, and enter offspring circulation through FcRn to provide protection beyond weaning. Natural transmission of virus from infected offspring to mothers establishes maternal immunity that protects future offspring, revealing a coordinated adaptive program that links maternal immune history, pregnancy, and lactation to optimize intergenerational immunity.
- 15 April 2025
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 20 (5) , 993-1003
Identification of a Selective Pharmacologic IRE1/XBP1s Activator with Enhanced Tissue Exposure
Activation of the IRE1/XBP1s signaling arm of the unfolded protein response (UPR) has emerged as a promising strategy to mitigate etiologically diverse diseases. Despite this promise, few compounds are available to selectively activate IRE1/XBP1s signaling to probe the biologic and therapeutic implications of this pathway in human disease. Recently, we identified the compound IXA4 as a highly selective activator of protective IRE1/XBP1s signaling. While IXA4 has proven useful for increasing IRE1/XBP1s signaling in cultured cells and mouse liver, the utility of this compound is restricted by its limited activity in other tissues. To broaden our ability to pharmacologically interrogate the impact of IRE1/XBP1s signaling in vivo, we sought to identify IRE1/XBP1s activators with greater tissue activity than IXA4. We reanalyzed 'hits' from the high throughput screen used to identify IXA4, selecting compounds from structural classes not previously pursued. We then performed global RNAseq to confirm that these compounds showed transcriptome-wide selectivity for IRE1/XBP1s activation. Functional profiling revealed compound IXA62 as a selective IRE1/XBP1s activator that reduced Aβ secretion from CHO7PA2 cells and enhanced glucose-stimulated insulin secretion from rat insulinoma cells, mimicking the effects of IXA4 in these assays. IXA62 robustly and selectively activated IRE1/XBP1s signaling in the liver of mice dosed compound intraperitoneally or orally. In treated mice, IXA62 showed broader tissue activity, relative to IXA4, inducing expression of IRE1/XBP1s target genes in additional tissues such as kidney and lung. Collectively, our results designate IXA62 as a selective IRE1/XBP1s signaling activating compound with enhanced tissue activity, which increases our ability to pharmacologically probe the biologic significance and potential therapeutic utility of enhancing adaptive IRE1/XBP1s signaling in vivo.
- 15 April 2025
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 20 (5) , 993-1003
Identification of a Selective Pharmacologic IRE1/XBP1s Activator with Enhanced Tissue Exposure
Activation of the IRE1/XBP1s signaling arm of the unfolded protein response (UPR) has emerged as a promising strategy to mitigate etiologically diverse diseases. Despite this promise, few compounds are available to selectively activate IRE1/XBP1s signaling to probe the biologic and therapeutic implications of this pathway in human disease. Recently, we identified the compound IXA4 as a highly selective activator of protective IRE1/XBP1s signaling. While IXA4 has proven useful for increasing IRE1/XBP1s signaling in cultured cells and mouse liver, the utility of this compound is restricted by its limited activity in other tissues. To broaden our ability to pharmacologically interrogate the impact of IRE1/XBP1s signaling in vivo, we sought to identify IRE1/XBP1s activators with greater tissue activity than IXA4. We reanalyzed 'hits' from the high throughput screen used to identify IXA4, selecting compounds from structural classes not previously pursued. We then performed global RNAseq to confirm that these compounds showed transcriptome-wide selectivity for IRE1/XBP1s activation. Functional profiling revealed compound IXA62 as a selective IRE1/XBP1s activator that reduced Aβ secretion from CHO7PA2 cells and enhanced glucose-stimulated insulin secretion from rat insulinoma cells, mimicking the effects of IXA4 in these assays. IXA62 robustly and selectively activated IRE1/XBP1s signaling in the liver of mice dosed compound intraperitoneally or orally. In treated mice, IXA62 showed broader tissue activity, relative to IXA4, inducing expression of IRE1/XBP1s target genes in additional tissues such as kidney and lung. Collectively, our results designate IXA62 as a selective IRE1/XBP1s signaling activating compound with enhanced tissue activity, which increases our ability to pharmacologically probe the biologic significance and potential therapeutic utility of enhancing adaptive IRE1/XBP1s signaling in vivo.